---
figid: PMC5978257__oncotarget-09-22680-g007
figtitle: Effect of the monoclonal antibody TRC105 in combination with Sunitinib on
  renal tumor derived endothelial cells
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC5978257
filename: oncotarget-09-22680-g007.jpg
figlink: /pmc/articles/PMC5978257/figure/F7/
number: F7
caption: In endothelial cells (EC), TRC105 blocks CD105 favouring the TGF-ß receptor/ALK5
  complex signaling. This complex phosphorylates and activates Smad 2/3 which can
  translocate in the nucleus leading to endothelial cell apoptosis. Sunitinib inhibits
  the signaling pathway of VEGF receptor 2 (KDR), resulting in a reduced Akt activity.
  In the presence of both drugs, Akt is synergistically inhibited by Sunitinib and
  by Smad 2/3 resulting in a reduced phosphorylation of the transcription factor Creb,
  involved in cell activation. Other tyrosine kinase inhibitors (Axitinib, Sorafenib
  and Cabozantinib), show a predominant modulation of the Erk pathway and do not affect
  Creb phosphorylation. No synergistic effect of TRC105 is present in combination
  with Axitinib, Sorafenib and Cabozantinib on VEGF receptor signaling pathways.
papertitle: Effect of the monoclonal antibody TRC105 in combination with Sunitinib
  on renal tumor derived endothelial cells.
reftext: Alessia Brossa, et al. Oncotarget. 2018 Apr 27;9(32):22680-22692.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9512579
figid_alias: PMC5978257__F7
figtype: Figure
redirect_from: /figures/PMC5978257__F7
ndex: fc82a137-def3-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5978257__oncotarget-09-22680-g007.html
  '@type': Dataset
  description: In endothelial cells (EC), TRC105 blocks CD105 favouring the TGF-ß
    receptor/ALK5 complex signaling. This complex phosphorylates and activates Smad
    2/3 which can translocate in the nucleus leading to endothelial cell apoptosis.
    Sunitinib inhibits the signaling pathway of VEGF receptor 2 (KDR), resulting in
    a reduced Akt activity. In the presence of both drugs, Akt is synergistically
    inhibited by Sunitinib and by Smad 2/3 resulting in a reduced phosphorylation
    of the transcription factor Creb, involved in cell activation. Other tyrosine
    kinase inhibitors (Axitinib, Sorafenib and Cabozantinib), show a predominant modulation
    of the Erk pathway and do not affect Creb phosphorylation. No synergistic effect
    of TRC105 is present in combination with Axitinib, Sorafenib and Cabozantinib
    on VEGF receptor signaling pathways.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - vegfaa
  - kdr
  - kdrl
  - acvrl1
  - smad2
  - smad5
  - smad1
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - TGFB1
  - TGFB2
  - TGFB3
  - KDR
  - TGFBR1
  - TGFBR2
  - TGFBR3
  - AKT1
  - AKT2
  - AKT3
  - ACVRL1
  - ALK
  - SLPI
  - SMAD1
  - SMAD4
  - SMAD5
  - SMAD6
  - SMAD7
  - SMAD9
  - SMAD2
  - SMAD3
  - EPHB2
  - MAPK1
  - MAPK3
  - GARS1
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - Axitinib
  - Sorafenib
  - Sunitinib
  - Cabozantinib
---
